Lamotrigine in typical absence epilepsy
Lamotrigine in typical absence epilepsy
复制标题
DOI：
10.1016/s0387-7604(99)00023-6
复制
发表时间：
1999-07-01
影响因子：
1.7
通讯作者：
Fois, A
中科院分区：
文献类型：
--
作者：
Buoni, S;Grosso, S;Fois, A
拉莫三嗪（LTG）是一种抗癫痫药，对部分性癫痫发作和全身性癫痫有效。越来越多的证据表明，LTG 对于对先前治疗有抵抗力的儿童 (CAE) 或青少年 (JAE) 缺勤很有用。在这项研究中，所有患者均使用严格的诊断标准进行识别，并分为两组。 (1) 8 名对丙戊酸或乙舒酰耐药的失神发作患者接受 LTG 作为附加治疗，(2) 7 名先前未接受治疗的典型失神发作患者在诊断后接受 LTG 单药治疗。在难治性失神发作患者中，癫痫发作得到了完全控制。其中 5 例患者在平均 12.5 个月后停用了之前的抗癫痫药物，仅接受 LTG 单一疗法。一名患者再次失神，因此在 LTG 中再次添加丙戊酸以重新控制癫痫发作。诊断后接受 LTG 单药治疗的 7 名患者中，有 6 名患者的癫痫发作得到了完全控制。第 7 名患者因皮疹而停药。 总之，LTG 与丙戊酸联合治疗似乎对难治性失神发作有效。此外，我们的初步数据表明，拉莫三嗪可用作典型失神发作的单一疗法。讨论了 LTG 单药治疗此类癫痫的优点和缺点。 (C) 1999 Elsevier Science B.V. 保留所有权利。
Lamotrigine (LTG) is an anti-epileptic drug effective in partial seizures and generalized epilepsy. There is growing evidence of the usefulness of LTG in childhood (CAE) or juvenile (JAE) absences resistant to previous treatment. In this study all patients were identified using strict diagnostic criteria and subdivided into two groups. (1) Eight patients affected by absence seizures resistant to valproic acid or ethosuximide, received LTG as an-add-on therapy, (2) seven patients affected by typical absence seizures not previously treated, received LTG monotherapy after the diagnosis. In the patients with resistant absence seizures, a full control of seizures was obtained. In five of them, after a mean period of 12.5 months, the previous anti-epileptic drugs were withdrawn leaving the patients on LTG monotherapy. In one patient, absences relapsed and valproic acid was therefore added again to LTG to regain control of the seizures. In six of the seven patients on LTG monotherapy after the diagnosis, a full control of seizures was obtained. In the seventh patient the drug was stopped due to a skin rash.In conclusion LTG appears to be effective in resistant absence seizures in combination with valproic acid. Moreover, our preliminary data suggest that lamotrigine might be used as monotherapy in typical absence seizures. The advantages and disadvantages of LTG monotherapy in this type of epilepsy are discussed. (C) 1999 Elsevier Science B.V. All rights reserved.